Brescia

• A Continuation Study of Latozinemab in Participants with Neurodegenerative Disease Ended
  2023-506805-20-01 5 2024-09-25 Neurodegenerative Diseases
• A study to learn about how well a new drug called BAY3283142 works and how safe it is in reducing albumin in the urine of people with chroni … Ended
  2023-505755-40-00 4 2024-08-16 Chronic kidney disease
• Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR Ended
  2023-507667-19-00 3 2024-06-06 Polymyalgia rheumatica (PMR)
• A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on subjects with Ataxia-Te … Ended
  2023-509077-23-00 5 2024-06-03 Ataxia Telangiectasia
• A study to learn how safe starting vericiguat at a dose of 5 milligrams is in participants with chronic heart failure with reduced ejection … Ended
  2023-507682-25-00 4 2024-05-13 Chronic heart failure with reduced ejection fraction
• EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended
  2023-505083-11-01 4 2024-05-07 Alzheimer's Disease
• MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended
  2023-506425-12-00 5 2024-04-17 Uncontrolled and Resistant Hypertension
• INSPIRE (INcreased Sun exposure without Pain In Research subjects with EPP). Ended
  2023-506735-15-00 5 2024-04-05 Erythropoietic Protoporphyria or X-Linked Protoporphyria
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myelo … Ended
  2023-505910-10-00 4 2024-01-23 Relapsed or Refractory High-Risk Myelodysplastic Syndrome
• A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibul … Ended
  2023-505487-11-00 5 2023-12-21 Actinic Keratosis on the Face or Scalp
• PH2a, VH3739937 Proof-Of-Concept in TN HIV-1 Infected Adults Ended
  2023-505780-37-00 4 2023-12-21 HIV Infections
• BRIGHT - A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug … Ended
  2022-502001-15-00 4 2023-12-05 Acute Ischemic Stroke (AIS)
• Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz … Ended
  2022-503148-41-00 4 2023-12-01 Alzheimer's disease
• A study to test whether BI 765845 helps people who have had a heart attack Ended
  2022-502788-39-00 4 2023-11-27 acute myocardial infarction
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2) Ended
  2022-501927-25-00 4 2023-09-29 Large B-Cell Lymphoma (LBCL)
• A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno … Ended
  2022-501885-24-00 5 2023-09-20 Contrast enhancement in magnetic resonance imaging for assessment of n
• A Phase 2 proof of concept study to evaluate the efficacy and safety of daxdilimab in participants with dermatomyositis or anti-synthetase i … Ended
  2022-502810-10-00 4 2023-09-12 Dermatomyositis (DM) or anti-synthetase inflammatory myositis (ASIM)
• SEER-3: A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of … Ended
  2022-502697-16-00 5 2023-08-29 Neurotrophic Keratopathy
• A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants with Heart Failure and … Ended
  2022-502382-25-00 4 2023-08-24 Heart Failure and Pulmonary Hypertension due to Left Heart Disease (WH
• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• A study evaluating the effects of GLPG3667 given as oral treatment for up to 24 weeks in adults with dermatomyositis Ended
  2022-501097-19-00 4 2023-08-09 dermatomyositis
• Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE study) Ended
  2022-501783-18-00 4 2023-07-21 Parkinson’s Disease

Showing 433–456 of 545 trials